Leerink Partners analyst Geoffrey Porges trims its price target on Regeneron Pharma (NASDAQ: REGN) to $511.00 (from $530.00) but maintains ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE